Page 5 - Jun Ma News Today

-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in...

Over the past several years, managing one's mental health has become more of a priority with an increased emphasis on self-care. Depression alone affects more than 300 million people worldwide annually.

Using Fitbits and a novel machine learning model, a multi-institutional team led by Washington University in St. Louis' Chenyang Lu is ushering in the next step in personalization for treatment of depression.

Researchers at the University of Illinois Chicago have been awarded approximately $3.3 million from the National Institute on Aging to study telehealth behavioral interventions among adults 50 and older with excess weight and cardiometabolic risk factors.

Results from a pilot clinical trial show that among a racially and ethnically diverse cohort of adults who were obese and depressed, an integrated behavioral intervention was more effective than usual care at reducing depression and associated anxiety symptoms than it was at promoting weight loss.

GuruFocus Article or News written by PRNewswire and the topic is about:

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors ...

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors --Toripalimab continues to demonstrate synergy as the

Investegate announcements from Junshi Biosciences, Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

For patients with head and neck cancer receiving chemoradiotherapy, higher doses of gabapentin may delay the time to first opioid use.